Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zafgen Finds Plentiful Funding in Slimmed Down Obesity Market

This article was originally published in Start Up

Executive Summary

The obesity-foucsed start-up Zafgen has emerged from stealth mode. Taking the reins as CEO is Thomas Hughes, PhD, former VP and global head of cardiovascular and metabolic disease at Novartis. With $22 million in funding from Atlas Venture and Third Rock Ventures, the company is well capitalized to drive its lead molecules into the clinic.

You may also be interested in...



Diabetes Drug Development: Seeing Light In The Dark Ages?

Tougher regulatory hurdles introduced three years ago extended the timelines for successful diabetes drug development, discouragiing investment and partnering activity. An ever-increasing incidence of diabetes, metabolic disorders, and obesity continues to drive innovation and the development of new medicines – but with less emphasis on novel mechanisms.

Obesity-Focused Zafgen Raises Zaftig Series B

Three years after its launch, Zafgen emerges from stealth mode with a new CEO and another $14 million in funding.

Obesity-Focused Zafgen Raises Zaftig Series B

Three years after its launch, Zafgen emerges from stealth mode with a new CEO and another $14 million in funding.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel